MEDX - ETF AI Analysis
Top Page
Horizon Kinetics Medical ETF (MEDX)
Rating:66Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and over the past few months, showing positive momentum.
High-Quality Healthcare Leaders
Many of the top holdings are large, well-known drug and biotech companies that have shown strong or steady performance.
Focused Exposure to Healthcare
The fund’s heavy tilt toward the health care sector gives investors targeted access to a key defensive area of the market.
Negative Factors
High Expense Ratio
The fund’s fees are relatively high for an ETF, which can eat into long-term returns.
Sector Concentration Risk
With most assets in health care, the ETF is vulnerable if this single sector faces regulatory or business headwinds.
Stock-Specific Weakness
A few notable holdings have shown weak performance, which can drag on the fund if those stocks do not recover.
MEDX vs. SPDR S&P 500 ETF (SPY)
AUM17.35M
RegionGlobal
Expense Ratio0.85%
Beta0.50
IssuerHorizon Kinetics
Inception DateJan 30, 2023
Dividend Yield1.17%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,883
30 Day Avg. Volume2,166
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.02Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDX Summary
The Horizon Kinetics Medical ETF (MEDX) is a health care-focused fund that invests in a wide mix of medical companies instead of tracking a single index. It holds businesses in areas like biotechnology, drug makers, medical devices, and health care providers. Well-known names in the fund include Eli Lilly and Johnson & Johnson. Someone might invest in MEDX to seek long-term growth from medical advances and an aging population, while spreading their money across many health care firms. A key risk is that the fund is heavily tied to the health care sector, so its price can rise or fall sharply if that industry struggles.
How much will it cost me?The Horizon Kinetics Medical ETF (MEDX) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care investments that require more research and expertise.
What would affect this ETF?The Horizon Kinetics Medical ETF (MEDX) could benefit from ongoing advancements in medical research, an aging global population driving demand for health care, and increased health awareness globally. However, challenges such as regulatory changes, patent expirations for major pharmaceutical companies, or economic downturns impacting health care spending could negatively affect its performance. With top holdings like Eli Lilly and AbbVie, the ETF's success is closely tied to the innovation and market conditions within the health care sector.
MEDX Top 10 Holdings
MEDX is very much a health care story, with big pharma and biotech calling the shots. Eli Lilly sits in the driver’s seat: despite a recent pause, its longer-term climb is a key engine for the fund. AbbVie, Johnson & Johnson, Merck, and Amgen form a steady core, keeping the portfolio on a generally upward path. On the flip side, AstraZeneca is losing steam and Ionis is clearly lagging, acting as small anchors. With a global mix of drugmakers but a heavy tilt toward a few giants, MEDX is concentrated yet still broadly diversified within health care.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 18.60% | $3.23M | $1.09T | 50.70% | 72 Outperform | |
| AbbVie | 9.48% | $1.64M | $454.79B | 28.54% | 66 Neutral | |
| Novartis | 7.29% | $1.27M | $287.33B | 35.43% | 80 Outperform | |
| Johnson & Johnson | 5.90% | $1.02M | $616.50B | 53.20% | 78 Outperform | |
| Alkermes | 5.53% | $958.82K | $8.39B | 84.52% | 80 Outperform | |
| Bristol-Myers Squibb | 5.21% | $904.15K | $132.45B | 47.66% | 78 Outperform | |
| AstraZeneca | 4.71% | $817.98K | $265.97B | 13.76% | 80 Outperform | |
| Amgen | 4.39% | $760.94K | $209.21B | 29.74% | 77 Outperform | |
| Merck & Company | 4.18% | $725.53K | $320.56B | 64.21% | 80 Outperform | |
| Ionis Pharmaceuticals | 3.19% | $553.05K | $8.85B | 20.31% | 61 Neutral |
MEDX Technical Analysis
Negative
―
Price Trends
35.05
Negative
33.94
Positive
33.52
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDX, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 35.67, equal to the 50-day MA of 35.05, and equal to the 200-day MA of 33.52, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MEDX.
MEDX Peer Comparison
Comparison Results
Performance Comparison
MEDX
Horizon Kinetics Medical ETF
34.92
7.10
25.52%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents